Loading...

Discounted Cash Flow (DCF) Analysis Unlevered


GW Pharmaceuticals Plc

GW Pharmaceuticals Plc (GWPH)

Healthcare

Operating Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -----------
Revenue (%)
EBITDA -----------
EBITDA (%)
EBIT -----------
EBIT (%)
Depreciation -----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Total Cash -----------
Total Cash (%)
Account Receivables -----------
Account Receivables (%)
Inventories -----------
Inventories (%)
Accounts Payable -----------
Accounts Payable (%)
Capital Expenditure -----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 102.65
Diluted Shares Outstanding 333.94
Cost of Debt
Tax Rate -1.30
After-tax Cost of Debt 0.12
Risk-Free Rate
Market Risk Premium
Cost of Equity 24.67
Total Debt 13.67
Total Equity 34,278.53
Total Capital 34,292.20
Debt Weighting 0.04
Equity Weighting 99.96
Wacc

Build Up Free Cash

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -----------
EBITDA -----------
EBIT -----------
Tax Rate -0.28%-0.28%-0.28%-0.28%0.75%-1.30%-0.28%-0.28%-0.28%-0.28%-0.28%
EBIAT -----------
Depreciation -----------
Accounts Receivable -----------
Inventories -----------
Accounts Payable -----------
Capital Expenditure -----------
UFCF -----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 24.67
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding 333.94
Equity Value Per Share -